ADGRL4 and neoplasm: Anti‐ELTD1, OKN and combined therapies, but not bevacizumab, were successful in decreasing the human mitochondrial positivity staining within the tumour region compared to untreated (Figure 4D–H) (anti‐ELTD1 vs UT **p = 0.0011; combined vs UT **p = 0.0062; OKN vs UT *p = 0.0128).